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Introduction  
It is thought that between a third and a half of all medicines1
There are many causes of non-adherence but they fall into two overlapping 
categories: intentional and unintentional. Unintentional non-adherence occurs 
when the patient wants to follow the agreed treatment but is prevented from 
doing so by barriers that are beyond their control. Examples include poor 
recall or difficulties in understanding the instructions, problems with using the 
treatment, inability to pay for the treatment, or simply forgetting to take it. 
 prescribed for 
long-term conditions are not taken as recommended. If the prescription is 
appropriate, then this may represent a loss to patients, the healthcare system 
and society. The costs are both personal and economic. 
Adherence presumes an agreement between prescriber and patient about the 
prescriber’s recommendations. Adherence to medicines is defined as the 
extent to which the patient’s action matches the agreed recommendations. 
Non-adherence may limit the benefits of medicines, resulting in lack of 
improvement, or deterioration, in health. The economic costs are not limited to 
wasted medicines but also include the knock-on costs arising from increased 
demands for healthcare if health deteriorates.  
Non-adherence should not be seen as the patient’s problem. It represents a 
fundamental limitation in the delivery of healthcare, often because of a failure 
to fully agree the prescription in the first place or to identify and provide the 
support that patients need later on.  
Addressing non-adherence is not about getting patients to take more 
medicines per se. Rather, it starts with an exploration of patients’ perspectives 
of medicines and the reasons why they may not want or are unable to use 
them. Healthcare professionals have a duty to help patients make informed 
decisions about treatment and use appropriately prescribed medicines to best 
effect.  
                                                 
1 In this guideline ‘medicines’ is used as a general term to refer to prescribed medicines that 
are self-administered and includes tablets, syrups, ointments, eyedrops and suppositories. 
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Intentional non-adherence occurs when the patient decides not to follow the 
treatment recommendations. This is best understood in terms of the beliefs 
and preferences that influence the person’s perceptions of the treatment and 
their motivation to start and continue with it. It follows that to understand 
adherence to treatment we need to consider the perceptual factors (for 
example, beliefs and preferences) that influence motivation to start and 
continue with treatment, as well as the practical factors that influence patients' 
ability to adhere to the agreed treatment. 
Applying this approach in practice requires: 
• a frank and open approach which recognises that non-adherence may be 
the norm (or is at least very common) and takes a no-blame approach, 
encouraging patients to discuss non-adherence and any doubts or 
concerns they have about treatment 
• a patient-centred approach that encourages informed adherence  
• identification of specific perceptual and practical barriers to adherence  
for each individual, both at the time of prescribing and during regular 
review, because perceptions, practical problems and adherence may 
change over time.  
This guideline makes recommendations about how healthcare professionals 
can help patients to make informed decisions by facilitating the involvement of 
patients in the decision to prescribe, and how they can support patients to 
adhere to the prescribed medicine. We have not made separate 
recommendations for carers and families. The principal relationship is 
between patient and healthcare professional, and the patient has a right to 
decide who should be involved in their care. With the patient's consent, carers 
should have access to appropriate levels of information and support.  
An increasing number of healthcare professionals are now involved in the 
prescribing, dispensing and reviewing of medicines. It is not within the remit of 
a guideline to recommend which healthcare professional carries out these 
roles. All healthcare professionals should be aware of and work within legal 
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and professional codes. Information and tools to support healthcare 
professionals can be found at www.npci.org.uk 
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Patient-centred care 
This guideline offers best practice advice on how to involve patients in 
decisions about prescribed medicines and how to support adherence.  
All NICE clinical guidelines state that treatment and care should take into 
account patients’ needs and preferences and patients should have the 
opportunity to make informed decisions about their care and treatment, in 
partnership with their healthcare professionals. Good communication between 
healthcare professionals and patients is essential. It should be supported by 
evidence-based written information tailored to each patient’s needs. 
If the patient agrees, families and carers should also have the opportunity to 
be involved in decisions about treatment and care. Families and carers should 
be given the information and support they need.  
If patients do not have the capacity to make decisions, healthcare 
professionals should follow the Department of Health guidelines – ‘Reference 
guide to consent for examination or treatment’ (2001) (available from 
www.dh.gov.uk). Healthcare professionals should also follow the code of 
practice that accompanies the Mental Capacity Act (summary available from 
www.publicguardian.gov.uk).  
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Key principles 
• Healthcare professionals should adapt their consultation style to the needs 
of individual patients so that all patients have the opportunity to be involved 
in decisions about their medicines at the level they wish. 
• Establish the most effective way of communicating with each patient and, if 
necessary, consider ways of making information accessible and 
understandable (for example, using pictures, symbols, large print, different 
languages, an interpreter or a patient advocate). 
• Offer all patients the opportunity to be involved in making decisions about 
prescribed medicines. Establish what level of involvement in 
decision-making the patient would like.  
• Be aware that increasing patient involvement may mean that the patient 
decides not to take or to stop taking a medicine. If in the healthcare 
professional’s view this could have an adverse effect, then the information 
provided to the patient on risks and benefits and the patient's decision 
should be recorded. 
• Accept that the patient has the right to decide not to take a medicine, even 
if you do not agree with the decision, as long as the patient has the 
capacity to make an informed decision and has been provided with the 
information needed to make such a decision.  
• Be aware that patients’ concerns about medicines, and whether they 
believe they need them, affect how and whether they take their prescribed 
medicines. 
• Offer patients information that is relevant to their condition, possible 
treatments and personal circumstances, and that is easy to understand and 
free from jargon.  
• Recognise that non-adherence is common and that most patients are 
non-adherent sometimes. Routinely assess adherence in a 
non-judgemental way whenever you prescribe, dispense and review 
medicines.  
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• Be aware that although adherence can be improved, no specific 
intervention can be recommended for all patients. Tailor any intervention to 
increase adherence to the specific difficulties with adherence the patient is 
experiencing. 
• Review patient knowledge, understanding and concerns about medicines, 
and a patient's view of their need for medicine at intervals agreed with the 
patient, because these may change over time. Offer repeat information and 
review to patients, especially when treating long-term conditions with 
multiple medicines.  
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1 Guidance 
The following guidance is based on the best available evidence. The full 
guideline (www.nice.org.uk/CG76FullGuideline) gives details of the methods 
and the evidence used to develop the guidance. 
These recommendations apply to all healthcare professionals who prescribe, 
dispense or review medicines or who have a role in making decisions about 
medicines with patients. Healthcare professionals are reminded of their duty 
under the Disability Discrimination Act (2005) to make reasonable 
adjustments to ensure that all people have the same opportunity for health.  
1.1 Patient involvement in decisions about medicines 
Communication 
Good communication between healthcare professionals and patients is 
needed for involvement of patients in decisions about medicines and for 
supporting adherence. Some patients may find it easier to communicate with 
their healthcare professional than others.  
1.1.1 Healthcare professionals should adapt their consultation style to 
the needs of individual patients so that all patients have the 
opportunity to be involved in decisions about their medicines at the 
level they wish. 
1.1.2 Consider any factors such as physical or learning disabilities, sight 
or hearing problems and difficulties with reading or speaking 
English, which may affect the patient's involvement in the 
consultation.  
1.1.3 Establish the most effective way of communicating with each 
patient and, if necessary, consider ways of making information 
accessible and understandable (for example, using pictures, 
symbols, large print, different languages, an interpreter or a patient 
advocate). 
1.1.4 Encourage patients to ask about their condition and treatment.  
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1.1.5 Ask patients open-ended questions because these are more likely 
to uncover patients’ concerns.  
1.1.6 Be aware that the consultation skills needed for increasing patient 
involvement can be improved. 
Increasing patient involvement 
Patient involvement in the decision-making process requires that healthcare 
professionals acknowledge patients' views about their condition and its 
treatment, and that both healthcare professional and patient have a role in 
making decisions about treatment. Simple interventions to increase patient 
involvement do not necessarily increase the overall length of consultation and 
may be justified by benefits, particularly over the course of a long-term 
condition. 
1.1.7 Offer all patients the opportunity to be involved in making decisions 
about prescribed medicines. Establish what level of involvement in 
decision-making the patient would like.  
1.1.8 Discuss with the patient why they might benefit from the treatment. 
Clearly explain the disease or condition and how the medicine will 
influence this.  
1.1.9 Explain the medical aims of the treatment to patients and openly 
discuss the pros and cons of proposed medicines. The discussion 
should be at the level preferred by the patient.  
1.1.10 Clarify what the patient hopes the treatment will achieve.  
1.1.11 Avoid making assumptions about patient preferences about 
treatment. Talk to the patient to find out their preferences, and note 
any non-verbal cues that may indicate you need to explore the 
patient’s perspective further.  
1.1.12 Healthcare professionals have a duty to help patients to make 
decisions about their treatment based on an understanding of the 
likely benefits and risks rather than on misconceptions.  
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1.1.13 Accept that patients may have different views from healthcare 
professionals about the balance of risks, benefits and side effects 
of medicines.  
1.1.14 Be aware that increasing patient involvement may mean that the 
patient decides not to take or to stop taking a medicine. If in the 
healthcare professional’s view this could have an adverse effect, 
then the information provided to the patient on risks and benefits 
and the patient's decision should be recorded. 
1.1.15 Accept that the patient has the right to decide not to take a 
medicine, even if you do not agree with the decision, as long as the 
patient has the capacity to make an informed decision and has 
been provided with the information needed to make such a 
decision.  
1.1.16 Assess the patient's capacity to make each decision using the 
principles in the Mental Capacity Act (2005) 
(www.opsi.gov.uk/ACTS/acts2005/ukpga_20050009_en_1). To 
lack capacity patients must: (a) have an impairment of or 
disturbance or malfunction of brain and mind, and (b) demonstrate 
lack of capacity to: 
• understand the information relevant to the decision 
• retain information for long enough to use it in the decision 
• use or weigh information as part of the process of making the 
decision 
• communicate the decision (whether by talking, using sign 
language or any other means).  
1.1.17 If the patient has specific concerns, record a summary of the 
discussion, because this may be helpful in future consultations.  
1.1.18 Encourage and support patients, families and carers to keep an 
up-to-date list of all medicines the patient is taking. The list should 
include the names and dosages of prescription and 
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non-prescription medicines and herbal and nutritional supplements. 
If the patient has any allergic or adverse reactions to medicines, 
these should be noted.  
Understanding the patient's knowledge, beliefs and concerns about 
medicines 
There is evidence that patients make decisions about medicines based on 
their understanding of their condition and the possible treatments, their view of 
their own need for the medicine and their concerns about the medicine.  
1.1.19 Be aware that patients’ concerns about medicines, and whether 
they believe they need them, affect how and whether they take 
their prescribed medicines. 
1.1.20 Ask patients what they know, believe and understand about 
medicines before prescribing new treatments and when reviewing 
medicines.  
1.1.21 Ask if the patient has any specific concerns about their medicines, 
whenever you prescribe, dispense or review medicines. These may 
include concerns about becoming dependent on medicines and 
concerns about adverse effects. Address these concerns.  
1.1.22 Be aware that patients may wish to minimise how much medicine 
they take.  
1.1.23 Be aware that patients may wish to discuss:  
• what will happen if they do not take the medicine suggested by 
their healthcare professional 
• non-pharmacological alternatives to medicines 
• how to reduce and stop medicines they may have been taking 
for a long time, particularly those known to be associated with 
withdrawal symptoms 
• how to fit taking the medicine into their daily routine 
• how to make a choice between medicines if they believe they 
are taking too many medicines.  
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Providing information 
Patients need information about their condition and possible treatments if  
they are to be involved in making informed decisions about medicines. The 
format and content of the information provided should meet the needs of 
individual patients. 
1.1.24 Offer patients information about medicines before the medicines 
are prescribed.  
1.1.25 Offer patients information that is relevant to their condition, possible 
treatments and personal circumstances, and that is easy to 
understand and free from jargon.  
1.1.26 Check that patients have any information they wish about 
medicines when the medicines are dispensed.  
1.1.27 Discuss information on medicines with the patient rather than just 
presenting it. The discussion should take into account what the 
patient understands and believes about the condition and 
treatment.  
1.1.28 Do not assume that the patient information leaflets (PILs)2
1.1.29 Patients differ in the type and amount of information they need and 
want. Therefore the provision of information should be 
individualised and is likely to include, but not be limited to: 
 that 
patients receive with their medicines will meet each patient's 
needs. Address concerns that patients may have after reading the 
standard PILs.  
• what the medicine is  
• how the medicine is likely to affect their condition (that is, its 
benefits)  
                                                 
2 Patient information leaflets (PILs) contain information for patients on how medicines should 
be used. It is a legal requirement that this information is included on the label or within the 
packaging of a medicine. 
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• likely or significant adverse effects and what to do if they think 
they are experiencing them 
• how to use the medicine  
• what to do if they miss a dose 
• whether further courses of the medicine will be needed after the 
first prescription 
• how to get further supplies of medicines. 
1.1.30 Be careful not to make assumptions about a patient’s ability to 
understand the information provided. Check with the patient that 
they have understood the information. Information for patients 
should be clear and logical and, if possible, tailored to the needs of 
the individual patient.  
1.1.31 Suggest where patients might find reliable information and support 
after the consultation: for example, by providing written information 
or directing them to other resources (for example, NHS Choices 
[www.nhs.uk]). 
1.1.32 Provide inpatients with the same information as patients in other 
settings. Information should include: 
• what the medicine is  
• how the medicine is likely to affect their condition (that is, its 
benefits)  
• likely or significant adverse effects and what to do if they think 
they are experiencing them 
• how to use the medicine  
• what to do if they miss a dose 
• whether further courses of the medicine will be needed after the 
first prescription 
• how to get further supply after discharge. 
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1.2 Supporting adherence 
Assessing adherence 
Patients do not always take their medicines exactly as prescribed, and 
healthcare professionals are often unaware of how patients take their 
medicines. The purpose of assessing adherence is not to monitor patients but 
rather to find out whether patients need more information and support. 
1.2.1 Recognise that non-adherence is common and that most patients 
are non-adherent sometimes. Routinely assess adherence in a 
non-judgemental way whenever you prescribe, dispense and 
review medicines.  
1.2.2 Consider assessing non-adherence by asking the patient if they 
have missed any doses of medicine recently. Make it easier for 
them to report non-adherence by: 
• asking the question in a way that does not apportion blame  
• explaining why you are asking the question 
• mentioning a specific time period such as ‘in the past week’ 
• asking about medicine-taking behaviours such as reducing the 
dose, stopping and starting medicines.  
1.2.3 Consider using records of prescription re-ordering, pharmacy 
patient medication records and return of unused medicines to 
identify potential non-adherence and patients needing additional 
support.  
Interventions to increase adherence 
Patients may need support to help them make the most effective use of their 
medicines. This support may take the form of further information and 
discussion, or involve practical changes to the type of medicine or the 
regimen. Any interventions to support adherence should be considered on a 
case-by-case basis and should address the concerns and needs of individual 
patients. 
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1.2.4 If a patient is not taking their medicines, discuss with them whether 
this is because of beliefs and concerns or problems about the 
medicines (intentional non-adherence) or because of practical 
problems (unintentional non-adherence). 
1.2.5 Be aware that although adherence can be improved, no specific 
intervention can be recommended for all patients. Tailor any 
intervention to increase adherence to the specific difficulties with 
adherence the patient is experiencing. 
1.2.6 Find out what form of support the patient would prefer to increase 
their adherence to medicines. Together, you and your patient 
should consider options for support. 
1.2.7 Address any beliefs and concerns that patients have that result in 
reduced adherence. 
1.2.8 Because evidence supporting interventions to increase adherence 
is inconclusive, only use interventions to overcome practical 
problems associated with non-adherence if a specific need is 
identified. Target the intervention to the need. Interventions  
might include: 
• suggesting that patients record their medicine-taking 
• encouraging patients to monitor their condition 
• simplifying the dosing regimen 
• using alternative packaging for the medicine 
• using a multi-compartment medicines system. 
1.2.9 Side effects can be a problem for some patients. If this is the case 
you should: 
• discuss how the patient would like to deal with side effects 
• discuss the benefits, side effects and long-term effects with the 
patient to allow them to make an informed choice 
• consider adjusting the dosage 
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• consider switching to another medicine with a different risk of 
side effects 
• consider what other strategies might be used (for example, 
timing of medicines).  
1.2.10 Ask patients if prescriptions charges are a problem for them. If they 
are, consider possible options to reduce costs.  
1.3 Reviewing medicines 
Patients may use medicines long term. The initial decision to prescribe 
medicines, the patient’s experience of using the medicines and the patient's 
needs for adherence support should be reviewed regularly. The patient's own 
list of medicines may be a useful aid in a medicines review. 
1.3.1 Review patient knowledge, understanding and concerns about 
medicines, and a patient's view of their need for medicine at 
intervals agreed with the patient, because these may change over 
time. Offer repeat information and review to patients, especially 
when treating long-term conditions with multiple medicines. 
1.3.2 Review at regular intervals the decision to prescribe medicines, 
according to patient choice and need.  
1.3.3 Enquire about adherence when reviewing medicines. If 
non-adherence is identified, clarify possible causes and agree any 
action with the patient. Any plan should include a date for a 
follow-up review.  
1.3.4 Be aware that patients sometimes evaluate prescribed medicines 
using their own criteria such as their understanding of their 
condition or the symptoms most troubling to them. They may, for 
example, stop and start the medicine or alter the dose and check 
how this affects their symptoms. Ask the patient whether they have 
done this.  
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1.4 Communication between healthcare professionals 
Patients may be under the care of healthcare professionals from different 
disciplines and specialties at the same time; responsibility for patients' care 
may be transferred between healthcare professionals, and medicines reviews 
may be carried out by healthcare professionals other than the prescriber. 
Therefore good communication between healthcare professionals is required 
to ensure that fragmentation of care does not occur. 
1.4.1 Healthcare professionals involved in prescribing, dispensing or 
reviewing medicines should ensure that there are robust processes 
for communicating with other healthcare professionals involved in 
the patient’s care.  
1.4.2 On transfer between services (for example, between hospitals and 
care homes or on discharge from hospital), give all patients and 
subsequent healthcare or other providers a written report 
containing: 
• the patient's diagnosis 
• a list of all medicines the patient should be taking 
• clear identification of any new medicines that were started  
• clear identification of any medicines that were stopped, with 
reasons 
• clear information on which medicines should be continued after 
transfer from that service and for how long 
• any known adverse reactions and allergies the patient has 
experienced 
• any potential difficulties with adherence and any actions taken 
(for example, provision of a multi-compartment medicines 
system).  
1.4.3 Healthcare professionals involved in reviewing medicines should 
inform the prescriber of the review and its outcome. This is 
particularly important if the review involves discussion of difficulties 
with adherence and further review is necessary.  
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2 Notes on the scope of the guidance 
NICE guidelines are developed in accordance with a scope that defines what 
the guideline will and will not cover. The scope of this guideline is available 
from www.nice.org.uk/CG76 
How this guideline was developed 
NICE commissioned the National Collaborating Centre for Primary Care to 
develop this guideline. The Centre established a Guideline Development 
Group (see appendix A), which reviewed the evidence and developed the 
recommendations. An independent Guideline Review Panel oversaw the 
development of the guideline (see appendix B). 
There is more information in the booklet: ‘The guideline development process: 
an overview for stakeholders, the public and the NHS’ (third edition, published 
April 2007), which is available from www.nice.org.uk/guidelinesprocess or 
from NICE publications (phone 0845 003 7783 or email 
publications@nice.org.uk and quote reference N1233). 
3 Implementation  
The Healthcare Commission assesses how well NHS organisations meet core 
and developmental standards set by the Department of Health in ‘Standards 
for better health’ (available from www.dh.gov.uk). Implementation of clinical 
guidelines forms part of the developmental standard D2. Core standard C5 
says that NHS organisations should take into account national agreed 
guidance when planning and delivering care. 
NICE has developed tools to help organisations implement this guidance 
(listed below). These are available on our website (www.nice.org.uk/CG76).  
• Slides highlighting key messages for local discussion. 
• National costing statement – gives some financial background and context 
to the guideline.  
• Guide to resources – gives information about a selection of resources 
available from NICE, government and other national organisations.  
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• Patient information resource – an information sheet for display in 
healthcare settings. 
• Audit support for monitoring local practice. 
4 Research recommendations 
The Guideline Development Group has made the following recommendations 
for research, based on its review of evidence, to improve NICE guidance and 
patient care in the future. The Guideline Development Group's full set of 
research recommendations is detailed in the full guideline (see section 5).  
4.1 Developing effective, equitable interventions to 
support adherence to appropriate prescriptions  
What are the most clinically effective and cost-effective methods for identifying 
and addressing the perceptual barriers (such as beliefs and concerns about 
medicines) that influence motivation to start and continue with treatment, and 
the practical barriers (such as limitations in personal capacity and resources) 
that limit an individual's ability to implement intentions to adhere to medicines? 
Why this is important 
The Guideline Development Group identified a priority for the systematic 
development of effective, realisable, efficient and equitable interventions to 
facilitate informed choice and optimal adherence to appropriately prescribed 
medicines. 
Systematic reviews of adherence interventions show that although adherence 
can be improved, the effects were generally modest and there is considerable 
room for improvement. Few previous interventions have been developed 
systematically using appropriate theoretical models, and they have not been 
modelled and piloted with assessment of process variables as well as 
outcomes.  
Interventions should be developed using an appropriate theoretical framework 
with a phased approach to testing that includes assessment of process (that 
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is, the things that are targeted for change) as well as outcomes and a need for 
an individual approach3
4.2 Informed choice and shared decision-making  
. 
What are the most clinically effective and cost-effective ways of 
communicating the potential benefits and risks of medicines to promote 
informed choice and optimal adherence? 
Why this is important 
The principles of informed choice and shared decision-making have largely 
been developed from theoretical and conceptual models. The competencies 
listed for shared decision-making consist of a number of different skills, and 
patients have shown that they may value different aspects of shared 
decision-making. Although the right of patients to be involved in 
decision-making in regard to their own healthcare is accepted, the practice of 
shared decision-making may mean that healthcare professionals and patients 
play different roles than they have to date in healthcare consultations. This 
may have implications for legal and professional responsibility and 
accountability. Patients and professionals enter decision-making with very 
different levels of knowledge and access to information. Improving patient 
knowledge and information may require structural changes to health services 
and their delivery. Patient-reported outcomes also need to be included. 
4.3 Support processes: prescribing-related consultations 
and medicines review  
How can practitioners and patients be supported to improve the quality of 
prescribing-related consultations and medicines reviews so that they facilitate 
informed choice and optimal adherence to medicines? 
What are the effects of medicines reviews by healthcare professionals other 
than the prescriber on patients, prescribers and outcomes? How can the 
process of medicines review be enhanced or improved to address issues of 
informed choice and adherence? 
                                                 
3 Campbell NC, Murray E, Darbyshire J et al. (2007) Designing and evaluating complex 
interventions to improve health care. BMJ 334: 455–9. 
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Why this is important 
Non-adherence is often a hidden problem. Many patients are reluctant to 
express doubts and concerns about medicines because they fear that it will 
displease the healthcare professional. We need better methods for 
overcoming this problem and promoting honest and open discussions about 
medicines and adherence.  
There are an increasing number of non-medical prescribers (such as 
pharmacists and nurses) This is a key context issue and there are a range of 
questions relating to patient perspectives on new prescribers and to new and 
existing prescribers’ perceptions and skills. The effects of new prescribers on 
patient adherence to medicines should be included in any studies designed to 
evaluate new prescribers. The inclusion of formal procedures for medicines 
review within the Pharmacy Contract in England provides an opportunity for 
improved support for patients. We need a better understanding of the effects 
of non-prescriber reviews on medicines usage and outcomes, and how 
reviews might be improved to benefit patients and society. 
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5 Other versions of this guideline 
5.1 Full guideline 
The full guideline, ‘Medicines adherence: involving patients in decisions about 
prescribed medicines and supporting adherence’ contains details of the 
methods and evidence used to develop the guideline. It is published by the 
National Collaborating Centre for Primary Care, and is available from our 
website (www.nice.org.uk/CG76FullGuideline).  
5.2 Quick reference guide 
A quick reference guide for healthcare professionals is available from 
www.nice.org.uk/CG76QuickRefGuide 
For printed copies, phone NICE publications on 0845 003 7783 or email 
publications@nice.org.uk (quote reference number N1759).] 
5.3 ‘Understanding NICE guidance’ 
Information for patients and carers (‘Understanding NICE guidance’) is 
available from www.nice.org.uk/CG76PublicInfo 
For printed copies, phone NICE publications on 0845 003 7783 or email 
publications@nice.org.uk (quote reference number N1760).  
We encourage NHS and voluntary sector organisations to use text from this 
booklet in their own information about enabling and supporting patients to 
make informed decisions about prescribed medicines. 
6 Related NICE guidance 
Technical patient safety solutions for medicines reconciliation on admission of 
adults to hospital. NICE patient safety guidance 1 (2007). Available from 
www.nice.org.uk/PSG001 
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7  Updating the guideline 
NICE clinical guidelines are updated as needed so that recommendations 
take into account important new information. We check for new evidence 
2 and 4 years after publication, to decide whether all or part of the guideline 
should be updated. If important new evidence is published at other times, we 
may decide to do a more rapid update of some recommendations.  
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This is a diagrammatic representation of a patient's journey and meetings with 
healthcare professionals at which medicines may be prescribed and 
dispensed. 
 





















Arrows indicate how patients’ attitudes are influenced by previous 
experiences of medicines and medicine-taking 
P–D encounter 
